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DISSERTATION ABSTRACT 
 
Jessica L. Preston 
 
Doctor of Philosophy 
 
Department of Biology 
 
December 2015 
 
Title: Overcoming the Current Limitations of Next-Generation Sequencing with New 
Methods for Local Assembly of Genomes and High-Specificity Rare Mutation Detection 
 
 
 
 
The relatively low cost of Next-Generation Sequencing (NGS) has enabled 
researchers to generate large amounts of sequencing data in order to identify disease-
causing mutations and to assemble simple genomes. However, NGS has inherent 
limitations due to the short DNA read lengths and high error rate associated with the 
technique. The short read lengths of NGS prevent the assembly of genomes with long 
stretches of repetitive DNA, and the high error rate prevents the accurate detection of rare 
mutations in heterogeneous populations such as tumors and microbiomes.  
I have co-developed new NGS methods to overcome these challenges. In order to 
increase the effective read length of NGS reads, local de novo assembly of short reads 
into long contigs can be achieved through the use of Paired-End Restriction-site 
Associated DNA Sequencing (RAD-PE-Seq). With the RAD-PE method, I sequenced a 
stickleback fosmid and generated contigs with an N50 length of 480 nucleotides. In order 
to eliminate false-positive mutations caused by the high error rate of NGS, the Paired-
End Low Error Sequencing (PELE-Seq) method was developed, which uses numerous 
quality control measures during the sequencing library preparation and data analysis steps 
 v 
 
in order to effectively eliminate sequencing errors. Control testing of the PELE-Seq 
demonstrates that the method completely eliminates false-positive mutations at 
sequencing read depths below 20,000X coverage, compared to a ~20% false-positive rate 
obtained with previous methods. The high accuracy of the PELE-Seq method allows for 
the detection of ultra-rare mutations in a genome, which was previously impossible with 
NGS. 
This dissertation includes previously published and unpublished co-authored 
material. 
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CHAPTER I 
INTRODUCTION 
 
The cost of genome sequencing has decreased dramatically in the last decade, and 
it is now possible to sequence a human genome for a few thousand dollars in a matter of 
days. Next-Generation DNA Sequencing (NGS) is a massively parallel, high-throughput 
process that generates sequence information for hundreds of millions of DNA molecules 
simultaneously. NGS has revolutionized molecular genetics, leading to the creation of the 
fields of transcriptomics and metagenomics, as well as others. The increased affordability 
of DNA and RNA sequencing has led to the generation of massive amounts of sequence 
data and new avenues of research. However, NGS is still a relatively new technique with 
some major limitations, namely, the short length of the sequencing reads (less than 500 
nucleotides) and the high error rates of the sequencer (~1%) [1,2,3]. The short read 
lengths of NGS platforms make it difficult to assemble genomes that contain highly 
repetitive regions, or to properly differentiate between alternative RNA isoforms[4,5]. 
The high error rates of the sequencing platform software and the polymerase enzymes 
used have led to an extremely high false positive rate, which makes it extremely 
challenging to accurately detect rare mutations present in a heterogeneous population, 
such as tumors or mitochondria [6,7]. The problems resulting from the short read lengths 
and high error rates associated with NGS pose challenges for researchers studying diverse 
topics ranging from evolutionary to clinical biology. This dissertation describes work 
done to address these problems through the development of new methods and techniques 
to overcome the inherent limitations of NGS. The first section describes a method 
  
 
2 
designed to overcome the problems associated with the short sequencing read length 
through the local assembly of short reads using restriction enzyme sites. The second 
section describes a method to reduce the error rate of NGS sequencing data using 
overlapping paired-end (PE) reads and a barcoding system. 
 
Local Assembly of Short Reads Using Restriction Sites 
 
One major shortcoming of the current high-throughput DNA sequencing methods 
is the short length of the sequence reads generated by the sequencing platforms [4,5]. For 
many applications, the short read length is not problematic and sequencing at a high read 
depth can generate enough information to assemble the short reads into contiguous 
sequences (contigs). Contigs are generated with programs that find where short 
sequencing reads overlap each other and then use that information to assemble them into 
one sequence. However, short sequencing read lengths are problematic in a variety of 
circumstances. Short read lengths interfere with genome assembly when the genome 
contains long stretches of repetitive regions, which is the case with most large genomes. 
If the stretches of repetitive sequences present in the genome are larger than the 
sequencing reads it is impossible to generate contigs by simply overlapping the sequence 
reads, as there is no way to know where the repetitive sequences begin and end. Another 
limitation resulting from short sequencing reads is the inability to infer information about 
the number and type of mRNA isoforms that have resulted from alternative splicing. 
Because each sequencing read is shorter than the length of a full mRNA transcript, it is 
impossible to piece together the various isoforms that were originally present in the 
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sample. Similarly, short sequencing read lengths also make it challenging to distinguish 
which homologous chromosome a sequencing read belongs to, hence it is difficult to 
determine haplotype information from a sample [3]. 
I have co-developed a new method to assemble short sequencing reads based on 
their position relative to restriction enzyme sites. Because restriction enzyme sites are 
found at specific sites throughout a genome, the short reads generated by sequencing each 
site can be grouped together and assembled locally into contigs. In order to generate 
longer contigs, it is useful to sequence as much of the genome space next to a restriction 
site as possible. The method, called RAD Paired-End Sequencing (RAD-PE Seq) is 
described in Chapter II, which is reproduced with permission from Etter PD, Preston JL, 
Bassham S, Cresko WA, Johnson EA, 2011, 6(4): e18561. Copyright 2011, PLoS ONE.  
 
Identifying and Filtering Next-Generation Sequencing Errors 
 
It is currently very challenging to detect rare mutations in genetically 
heterogeneous populations such as tumors and microbiomes with NGS, due to the 
relatively high error rates of NGS sequencing platforms and polymerase enzymes [6,7]. 
When sequencing a sample at 100x depth of coverage, the 1% error rate of current 
Illumina sequencers can lead to the generation of one error at every position in the 
genome. These sequencing and PCR errors are difficult to distinguish from true rare 
genetic variants using current methods. I have co-developed a new variant-calling method 
that drastically reduces the incidence of sequencing errors, called Paired-End Low Error 
Sequencing (PELE-Seq). The PELE-Seq method is described in Chapter III, which has 
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been submitted for publication as Preston JL, Royall A, Randel MA, Sikkink KL, Phillips 
PC, and Johnson EA, 2015 “High-Specificity Next-Generation Sequencing of Minor 
Alleles with Paired-End Low Error Sequencing (PELE-Seq)” (submitted to BMC 
Genomics). 
 
  
  
 
5 
CHAPTER II 
LOCAL GENOME ASSEMBLY OF SHORT SEQUENCING READS USING 
RESTRICTION SITES 
 
This work was published as Etter PD, Preston JL, Bassham S, Cresko WA, 
Johnson EA. Local De Novo Assembly of RAD Paired-End Contigs Using Short 
Sequencing Reads. 2011, 6(4): e18561. Copyright 2011, PLoS ONE. Eric Johnson and 
Paul Etter developed the RAD-PE method. I generated the data (partial-digest RAD-PE 
in stickleback fosmids). Eric Johnson performed data analysis. Eric Johnson and Bill 
Cresko were the principal investigators for this work. 
 
Introduction 
 
Despite the power of massively parallel sequencing platforms, de novo assembly 
of genomes with the short reads produced remains difficult. We demonstrate that short 
reads can be locally assembled into larger contigs using paired-end sequencing of 
restriction-site associated DNA (RAD-PE) fragments. We use this RAD-PE contig 
approach to sequence E. coli and stickleback genomic DNA with overlapping contigs of 
several hundred nucleotides. RAD-PE contigs mitigate the problem of short reads by 
creating much longer high-quality contigs appropriate for SNP discovery or the de novo 
assembly of genomes. 
The decreased cost and throughput increases offered by next-generation 
sequencing platforms create the ability to produce high coverage of a genome in a short 
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time.  However, it remains difficult to move from many millions of short reads to a high-
quality assembled genome, as the short sequence read lengths and the high error rates 
create computational difficulties. Several algorithms have been developed to more 
efficiently work with short read datasets [1,2,3], but these approaches require costly 
computing resources to compare each sequence read against all others [1,2,3,4].  
One difficulty in assembling a genome from short reads is bridging repetitive 
sequences. These sequences may exist in thousands to millions of locations in a genome, 
and are nearly indistinguishable in the context of a short sequence read. Without a way to 
place each repetitive sequence in its proper genomic location, it is difficult to move 
beyond producing a genome sequence made of many shorter contigs. Traditional 
solutions to this problem have included physically breaking the genome into smaller 
fragments, then cloning and sequencing each fragment independently, thereby ensuring 
that each repetitive sequence can be localized to a small region of the genome. The 
complexity reduction created by physically isolating a shorter genomic fragment is 
laborious, but remains one of the few true solutions to the challenges of assembling a 
complex genome.  
RAD tags are based on a different sort of complexity reduction step that samples 
the DNA flanking each instance of a particular restriction site in the genome [5,6,7,8]. 
RAD tags were developed to speed discovery of SNPs and have been particularly 
attractive in systems lacking a reference genome. However, moving from SNPs identified 
by sequencing RAD tags to a high-throughput genotyping platform is difficult without a 
reference genome, as these platforms typically require more than 60 nucleotides of 
flanking genomic DNA on both sides of the SNP of interest.   
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A distinctive feature of RAD tags is the asymmetric nature of the DNA fragments. 
Each RAD tag has one end defined by the restriction enzyme recognition site, and the 
other end defined by random shearing. Next-generation sequencers now have the 
capability to carry out paired-end reads, in which the two ends of a DNA fragment are 
sequenced and the two end sequences are known to belong to the same fragment. Paired-
end sequencing enables RAD fragments to be used for local de novo assembly. A typical 
RAD library may contain 10,000 to 100,000 RAD sequences. The sheared-end sequences 
that share a common RAD-site sequence are all derived from the same small region near 
the RAD site. This small set of sheared-end sequences can be assembled into a larger 
contig. Instead of a single, computationally intense assembly using the many sequence 
reads from the entire genome, RAD paired-end contig assembly is performed using only 
a small portion of the data at a time. Because the sequence reads come from a small 
region, the difficulties of finding significant sequence overlap and dealing with sequence 
errors become simpler. To demonstrate the power of this approach, we have created 
created RAD-PE contigs after a partial digest with a restriction enzyme that cuts at high 
frequency to generate overlapping contigs in stickleback.  
 
RAD Paired-End Contig Library Generation 
 
The DNA fragments created by RAD tag library preparation have a restriction site 
at one end and are randomly sheared at the other. This arrangement, when combined with 
Illumina paired-end sequencing, results in each instance of a restriction site sequence 
being sampled many times by the first reads and the genomic DNA sequence in the 
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nearby region being randomly sampled at a lower coverage by the second reads. We 
hypothesized that the explicit linking of second reads that sample a genomic region with 
a common first read RAD sequence would allow the second reads to be assembled on a 
local basis, one RAD site at a time (see Figure 2.1). 
We tested this approach by modifying the sequenced RAD tag protocol [6] in 
order to create paired-end compatible libraries. We altered two key aspects of the RAD 
protocol. First, a wider size range of fragments (300-800 bp) was isolated after shearing. 
The size of contigs assembled from the paired-end reads is dependent on the size range of 
fragments selected during library construction. Second, a longer, divergent P2 adapter 
that contains the reverse sequencing primer sequence was ligated to the variable end of 
the RAD tags before amplification, allowing the randomly sheared end of the RAD 
fragments to be sequenced by the second read. In order to make RAD-PE contigs useful 
for de novo assembly of whole genomes, and to achieve high coverage of a whole 
genome, libraries were created by partially digesting with a high-frequency restriction 
enzyme, which produced overlapping DNA fragments several kb long that were suitable 
for shearing (Figure 2.2A). As a result, RAD cut sites are typically only a few hundred 
base pairs apart, but the sheared ends sample 500 bp regions to the left and right of each 
RAD site.  
 
Partial-Digest RAD Paired-End Libraries for De Novo Assembly in Stickleback  
 
We tested the performance of this partial-digest RAD-PE contig protocol by 
sequencing a fosmid from stickleback. After partially digesting the DNA using two 
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restriction enzymes with different 4 bp recognition sequences, NlaIII and Sau3AI, 1.0-5.0 
kb DNA fragments were isolated prior to P1 ligation and shearing. Partially digested 
DNA samples were then carried through the RAD-PE contig protocol as described above. 
 
 
Figure 2.1. RAD paired-end contig libraries. (A) DNA fragments created by RAD tag 
library preparation have a restriction site (orange) at one end and a random sheared-end 
sequence (light brown) at the other. (B) Paired-end sequencing of RAD tag libraries 
allows the assembly of the sheared-end sequences from each RAD tag (dark brown) to be 
locally assembled into contigs on an individual basis (C). The distance at which the 
random end sequence lies, and hence the length of the contigs assembled, is dictated by 
the amount of shearing and the size of fragments isolated during the gel extraction step in 
the protocol. 
 
 
Because the samples were over-sequenced (>3 million reads total), we removed 
reads that increased coverage over a 30x threshold, leaving 2 million reads for the 
assembly. We also tuned the Velvet parameters for each RAD site using a script that 
A)
B)
Restriction sites in genome
RAD tag sequence read  Sheared-end reads
Variable length RAD tags isolated
Contigs assembled for each RAD tag fr om the sheared-end reads
C)
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tested three different word lengths and chose the assembly with the longest total contig 
lengths for that site (Figure 2.2B). The partial-digest strategy produced overlapping 
contigs as predicted (see Figure 2.2C) with an N50 length of 481 nucleotides; however, 
the assembled contigs mapped to two different regions of the genome, suggesting there 
were two fosmids present in the original prep. 
 
Methods 
 
Stickleback genomic DNA was isolated from pectoral fin clips using the DNeasy 
Tissue Kit (Qiagen). E. coli genomic DNA was acquired from the REL606 strain 
(provided by the Bohanan lab, UO) and from type B cells, ATCC 11303 strain (USB 
Corporation). Stickleback fosmids were isolated from genomic DNA using the 
CopyControl™ Fosmid Library Production Kit (Epicentre). 
1.0 μg of genomic DNA from each individual (H2 -141, L2-110) was digested for 
60 min at 37° C in a 50 μl reaction volume containing 5.0 μl 10x Buffer 4 and 10 units 
(U) SbfI-HF (New England Biolabs [NEB]). Samples were heat-inactivated for 20 min at 
65° C. 4.0 μl of barcoded SbfI-P1 Adapter (100 nM), a modified Illumina adapter 
(2006 Illumina, Inc., all rights reserved; top oligo:  5’- 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCC
GATCTxxxxxTGC*A-3’ [xxxxx = barcode (AGAGT-H2; CAGTC-L2), * = 
phosphorothioate bond]; bottom oligo:  5’-Phos-
xxxxxAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGGTCG
CCGTATCAT*T-3’), was added to each sample along with 0.6 μl rATP (100mM, 
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Promega), 1.0 μl 10x NEB Buffer 4, 0.5 μl (1000 U) T4 DNA Ligase (high 
concentration, NEB), 3.9 μl H2O and incubated at room temperature (RT) for 30 min. 
Samples were again heat-inactivated for 20 min at 65° C, combined, and randomly 
sheared (Bioruptor) to an average size of 500 bp. The sheared sample was purified using 
a QIAquick Spin column (Qiagen) and run out on a 1.25% agarose (Sigma), 0.5x TBE 
gel. 
 
Figure 2.2. De novo assembly of a fosmid using Partial-digest RAD paired-end libraries 
in stickleback. (A) Incomplete digestion of DNA with a frequently cutting restriction 
enzyme creates overlapping restriction fragments. Preparing RAD-PE libraries from a 
stickleback fosmid following partial digestion with two frequent cutters resulted in 
contigs up to 1000 bp long and an N50 length of 481 nucleotides. (B) Shows the 
distribution of contigs built from the two libraries. (C) Mapping the contigs (black bars) 
from each RAD tag (grey boxes) back to the stickleback reference sequence 
demonstrated overlapping coverage over an ~40 kb stretch of the genome with a zoom on 
part of the assembly displayed below. 
Restriction sites in genome
Partial digest
Full digest
A) B)
C)
9345k      9346k            9347k               9348k   9349k         9350k               9351k               9352k     9353k           9354k               9355k 9356k       9357k    
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A smear of DNA approximately 300-800 bp was isolated with a clean razor blade 
and purified using the MinElute Gel Extraction Kit (Qiagen). The Quick Blunting Kit 
(NEB) was used to polish the ends of the DNA in a 25 μl reaction volume containing 2.5 
μl 10x Blunting Buffer, 2.5 μl dNTP Mix and 1.0 μl Blunt Enzyme Mix. The sample was 
purified and incubated at 37° C for 30 min with 10 U Klenow Fragment (3-5 exo-, 
NEB) in a 50 μl reaction volume with 5.0 μl NEB Buffer 2 and 1.0 μl dATP (10 mM, 
Fermentas), to add 3 adenine overhangs to the DNA. After another purification, 1.0 μl of 
Paired-End-P2 Adapter (PE-P2; 10 μM), a divergent modified Illumina adapter (2006 
Illumina, Inc., all rights reserved; top oligo: 5’-Phos-
GATCGGAAGAGCGGTTCAGCAGGAATGCCGAGACCGATCAGAACAA-3, 
bottom oligo: 5-
CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTC
TTCCGATC*T-3), was ligated to the DNA fragments at RT. The sample was purified 
and eluted in 50 μl. 25 μl of the eluate was digested again with SbfI for 30 min to remove 
rare genomic DNA concatemers formed from re-ligation of short fragments with two SbfI 
restriction sites within 500 bp. The sample was purified, eluted in 50 μl and quantified 
using the Quant-iT™ dsDNA HS Assay Kit and Qubit™ fluorometer (Invitrogen). ~40 
ng was used as template in a 100 μl PCR amplification with 50 μl Phusion Master Mix 
(NEB) and 4.0 μl modified Illumina amplification primer mix (10 μM, 2006 Illumina, 
Inc., all rights reserved; P1-forward primer:  5-AATGATACGGCGACCACCGA-3, P2-
reverse primer:  5-CAAGCAGAAGACGGCATACGA-3). Phusion PCR settings 
followed product guidelines (NEB) for a total of 14 cycles with an annealing temperature 
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of 65° C. The library was cleaned through a column and gel purified, excising DNA 
~350-850 bp in size in an inverted triangle shape. PCR amplification of a wide-range of 
fragment sizes often results in biased representation of amplified products with an 
increased number of short fragments. We found this to be true in our current protocol, but 
reduced the effects by selecting a triangular slice during gel extraction to reduce the level 
of short fragment lengths from the PCR reaction. The sample was diluted to 10 nM and 
sequenced on the Paired-end module of the Genome Analyzer II following Illumina 
protocols for 2x60 bp reads. Sequences are available at the NCBI Short Read Archive 
(http://www.ncbi.nlm.nih.gov/Traces/sra; accession number SRA024496.1). 
Raw sequence reads were processed using custom Perl scripts (by Eric A. 
Johnson), to optimize read number and reduce artifacts within the data. Barcodes, if 
present, were trimmed from the raw reads.  Reads with many poor quality scores were 
removed. The number of reads from each RAD site was tracked, and RAD sequences 
above a threshold were considered repetitive and removed. Single mismatch derivatives 
of these repetitive RAD sequences were also removed. RAD sites with a number of reads 
below a threshold were also removed from further analysis, as the associated paired-end 
reads would therefore lack sufficient coverage for calling SNPs or were likely to be 
sequence-error created artifacts. 
The paired-end reads from each passing RAD site passing the above tests were 
sent to the Velvet assembler with a word length parameter that increased with increasing 
depth. Separate Velvet assemblies were also run with a fixed low and high word length, 
and the best assembly was chosen from the three trials based on the total assembled 
length of contigs. For the long insert assembly, the paired-end reads from each RAD site 
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were assembled with a word length of 41. The paired-end reads were re-assembled with a 
predicted optimal word length based on coverage and the first assembly contigs included 
as long read sequences to help guide the assembly at repeats. 
SNP calling was performed by aligning the sequence reads from each individual 
to the assembled contigs with Novoalign. Mismatches were filtered to include only high 
quality nucleotides and tracked by sample. SNPs were called using a simple thresholding.    
Multiple digestion reactions were set up for each DNA sample containing either 
1.0 μg of each fosmid DNA sample (BP11.12H 7e2 sox9) or 2.0 μg of E. coli REL606 
genomic DNA, 5.0 μl 10x Buffer 4, 100 μg/ml BSA and 2 U of NlaIII or Sau3AI (NEB). 
The reactions were incubated at 37° C in a 50 μl reaction volume for multiple lengths of 
time in order to achieve a spectrum of partially-digested to fully-digested DNA 
fragments. Digested samples were heat-inactivated for 20 min at 65° C and run out on a 
1.0% agarose gel. A smear of DNA approximately 1.0-5.0 kb was isolated for each 
sample with a clean razor blade and purified. The isolated samples were quantified and 
the remaining DNA was ligated to enzyme-specific P1 Adapters (1.0 μM), modified 
Illumina adapters (2006 Illumina, Inc., all rights reserved; NlaIII-P1 top oligo:  5’-
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCC
GATCTCATG-3’; NlaIII-P1 bottom oligo:  5’-Phos--
AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGGTCGCCGT
ATCATT-3’; Sau3AI-P1 top oligo:  5’-
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCC
GATCT-3’; Sau3AI-P1 bottom oligo:  5’-Phos-
GATCAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGGTCG
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CCGTATCATT-3’), as described above, at a 10:1 molar ratio of adapter to DNA ends 
(assuming an average genomic DNA fragment length of 3.25 kb). Samples were heat-
inactivated for 20 min at 65° C and randomly sheared to an average size of 500-800 bp. 
Sheared samples were purified, run out on a 1.0% gel and DNA smears 200-800 bp (200-
1200 bp for the E. coli samples) were isolated and purified. DNA polishing and 3 dA-
overhang addition was carried out as described. PE-P2 ligations were carried out with 0.5 
μl PE-P2 Adapter. Samples were purified, eluted in 50 μl and quantified. 20 ng of 
template was used in a 100 μl, 14-cycle Phusion PCR amplification with 25 μl Master 
Mix and 2.0 μl amplification primer mix. Libraries were cleaned and gel purified, 
excising DNA ~250-850 bp (250-1250 bp for the E. coli samples) in a triangle shape as 
above, diluted to 10 nM, and sequenced on the Paired-end module of the Genome 
Analyzer II following Illumina protocols for 40x80 bp reads. 
 
 
Discussion 
 
RAD tags are typically used to sample a portion of the genome, allowing high 
coverage at a desired number of loci. However, we modified the protocol to produce 
RAD-PE contigs that overlap over a genome using partial-digests with a frequent cutter. 
The advantage of this approach is that the short read sequences are first assembled into 
contigs, which can then be ordered into a genome-wide assembly. Whereas whole 
genome shotgun assemblies require specialized and expensive computational resources, 
RAD-PE contigs can be assembled on any computer.  
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The many challenges of whole genome assembly are mitigated by local assembly. 
Short read sequences have a high error rate, so for a whole genome assembly every 
sequence must be searched against all others using relaxed alignment parameters. But 
then related regions of the genome and repeats become indistinguishable. Also, 
sequences must have a long region of overlap to be pieced together in whole genome 
assemblies, as shorter words are found throughout the genome. When RAD-PE contigs 
are assembled, the small region size allows for easy alignment of even high-error 
sequences, and short regions of overlap are sufficient to piece sequences together. 
Genome assembly programs like Velvet require the user to choose parameters 
such as word length and expected coverage. Even the best whole genome shotgun 
methods create peaks and valleys of coverage across a genome and the genome itself has 
regions of low and high complexity. Despite this variation, during assembly a median 
value for each parameter is chosen and the assembler therefore is less optimal in those 
regions that differ from that median. Our scripts collect the reads from a particular region 
and attempt to optimize the assembly for that single region by removing excessive reads 
and adjusting the indexing word length in response to the predicted coverage, with low 
coverage assemblies using a short word length, allowing sparse reads to join together and 
high coverage assemblies using a longer word length to bridge non-unique short 
sequences in the region. We also routinely tried a fixed low, fixed high and this predicted 
optimal word length for each region and evaluated the results to choose the best assembly 
for further use. Velvet can be recompiled to use longer word lengths than the default 
maximum of 31, but this greatly increases the memory requirements for an assembly. 
While this is a problem for whole genome shotgun assemblies that already require 
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hundreds of gigabytes of memory, we took this step for our assembly of the long-insert 
RAD-PE contigs without difficulty due to the low memory requirements of local 
assembly. 
We showed the utility of using RAD-PE contigs for de novo assembly of large 
genomic regions by performing a partial-digest RAD-PE contig approach on a fosmid 
from stickleback using two different high-frequency cutters. 
RAD paired-end contigs provide a low-cost method for SNP discovery in a format 
suitable for high-throughput genotyping platforms that require flanking sequence for 
primer design. It is possible to use platforms such as Roche 454 to achieve similar read 
lengths; however, accurate SNP discovery requires low error rates and sufficient depth of 
coverage to sample both chromosomes and determine heterozygosity. Although pricing 
of sequencing platforms rapidly change, a similar SNP discovery project using the 454 
platform would currently cost more than ten times as much as RAD-PE contig 
sequencing. The 8 million reads used to create greater than 50,000 contigs and find more 
than 40,000 SNPs between the two stickleback samples are, at this time, just one quarter 
of a single Illumina GAIIx lane (1/28th of a run), whereas similar coverage would require 
at least one half of a full 454 run.  
A related strategy to RAD paired-end contigs, termed subassembly, was recently 
described [3]. The complexity reduction step in subassembly is achieved randomly by 
dilution and amplification rather than restriction digestion, and subassemblies use the end 
sequence of the amplified fragments as an index rather than a restriction cut site 
sequence. As a result, subassembly does not create contigs at the same loci between 
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samples, making the several hundred nucleotide contigs it produces useful for de novo 
assembly rather than SNP discovery.   
There is justified excitement over the next generation of sequencing platforms, 
which promise longer read lengths and simpler informatics. The longer assembly lengths 
created by long-insert RAD-PE contigs match the several kilobase output projected for 
the next generation of high-throughput sequencers, and the local assembly step also 
simplifies the computational needs of a de novo assembly project. While the next 
generation of sequencers currently suffer from a high error rate, RAD-PE contigs have a 
low error rate due to high coverage of any particular nucleotide. Therefore, users of high 
count, short read length sequencers can enjoy many of the benefits of long read lengths 
without the considerable expense of purchasing new systems and trouble of substantially 
altering their workflows.  
Besides the short read lengths of current NGS sequencing platforms, the other 
major shortcoming of current DNA sequencing technology is the relatively high error rate 
of the DNA sequences generated with standard methods. This error rate is highly 
problematic when attempting to sequence genetically heterogeneous populations such as 
tumors or microbiomes to detect mutations present at below 1% of the population. To 
overcome these challenges, the PELE-Seq method was developed, which is described in 
Chapter III. 
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CHAPTER III 
IDENTIFYING AND FILTERING NEXT-GEN SEQUENCING ERRORS 
 
This work has been submitted to BMC Genomics as Preston JL, Royall A, Randel 
MA, Sikkink KL, Phillips PC, and Johnson EA, 2015 “High-Specificity Next-Generation 
Sequencing of Minor Alleles with Paired-End Low Error Sequencing (PELE-Seq).” The 
sequencing procedure and data analysis pipeline described in this chapter was developed 
by a number of lab members, including myself, Eric Johnson, and Ariel Royall. Paul 
Etter contributed substantially to this work by participating in the development of the 
method. I was the primary contributor to the optimization of the method and generated all 
the data. I developed the data analysis procedure and did all of the writing. 
 
Introduction 
 
Populations with high levels of genetic heterogeneity are able to evolve rapidly 
through natural selection, for example providing the basis for drug resistance in 
populations of microbes, viruses, and tumor cells [1, 2, 3]. In order to understand how 
these heterogeneous populations evolve in response to selection, it is important to be able 
to characterize the full catalog of genetic variation present in the population, including de 
novo mutations and minor alleles. The reduced cost of DNA sequencing has powered the 
wide-scale discovery of functional and disease-causing single nucleotide polymorphisms 
(SNPs) and genomic regions under selection [4]. However, the current high error rate 
(~1%) leads to the generation of millions of sequencing errors in a single experiment. 
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Thus, when attempting to sequence de novo mutations or genetically heterogeneous 
populations, it is challenging to distinguish between sequencing errors and true rare 
genetic variants [5,6,7,8].  
Sequencing error reduction through the use of overlapping read pairs (ORPs) has 
been described previously by Chen-Harris et al., who showed that the use of overlapping 
paired-end reads dramatically reduces the occurrence of sequencing errors [9]. PELE-Seq 
improves on the ORP method by incorporating dual-barcoding to filter out many types of 
PCR errors and library preparation artifacts, as well as a data analysis strategy that 
increases the specificity of SNP detection without a loss in sensitivity. The PELE-Seq 
method is simple to use, compatible with most sequencing libraries, and doesn’t require 
the use of special reagents. The PELE-Seq error-reduction method is based on two 
principles. First, sequencing errors can be removed by sequencing each DNA molecule 
twice with overlapping reads and merging the reads into overlapping read pairs (ORPs). 
Any bases that are mismatched in the two sequences are excluded from the final SNP 
calling analysis. Second, PCR errors and library preparation artifacts are reduced through 
the use of a dual-barcoding system, which can be used to generate information about the 
number of independent occurrences of a genetic variant in a DNA sequencing library. 
The PELE-Seq variant calling analysis pipeline incorporates information from the 
barcoding data as well as the overlapping read pair data, and is optimized to allow for the 
highly sensitive detection of rare polymorphisms compared to standard methods of DNA 
sequencing.   
We applied the PELE-Seq method to sequence rare alleles in a wild population of 
Caenorhabditis remanei nematode worms. C. remanei are highly heterogeneous, non-
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hermaphroditic nematode worms that are amenable to studies investigating the genetic 
basis of the response to natural selection [10]. In this study, we sampled the genome of an 
ancestral population originating from 26 wild mating pairs from Toronto, Ontario that 
were lab-propagated for a total of 34 generations. We show that PELE-Seq can detect 
changes in the rare allele frequencies between the genomes of the wild and lab-adapted 
populations, and that PELE-Seq can detect low-frequency alleles that appear only in the 
laboratory adapted population. 
 
PELE-Seq Library Preparation and Data Analysis 
 
PELE-Seq improves the specificity of standard SNP calling methods by reducing 
the occurrence of false-positive sequencing errors in the data. An overview of the PELE-
Seq method is illustrated in Figure 3.1. PELE-Seq library preparation and analysis 
involves two separate error filtering steps which are combined during analysis: 
 
1. Illumina 100 bp paired-end sequencing of short 100 bp DNA inserts is used to generate 
two completely overlapping paired-end reads from each DNA molecule. The overlapping 
paired-end reads are then merged into one high-quality consensus sequence. After 
trimming off the overhanging bases and filtering for high quality scores, the resulting 
consensus sequence has a much lower incidence of false positive SNPs compared to the 
non-overlapped reads.  
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2. PCR errors and library preparation artifacts are reduced through the use of a dual-
barcoding system, which requires the presence of two independent occurrences of a 
variant. During library preparation, two independent barcodes are ligated to the DNA 
molecules to be sequenced. Then, during data analysis, SNPs that are present with only a 
single barcode are excluded from the analysis, as they are potential PCR errors or library 
preparation artifacts. 
 
PELE-Seq data analysis uses a multi-step variant calling approach to incorporate 
information from both the barcoding and the overlapping steps, without a large drop in 
sensitivity. Rare alleles are evaluated with the program LoFreq, which calls somatic 
variants using a Bonferroni-corrected P-value threshold of 0.05 [11]. Rare nucleotides are 
included in the final variant calling only if they pass two separate quality control steps: 1. 
The nucleotide is present in both overlapping sequence reads from a single DNA 
molecule and is called as a SNP when variants are called from the merged reads. 2. The 
nucleotide is called as a SNP in two separate instances of high-sensitivity variant calling, 
once for each barcode file. The final outcome of the PELE-Seq analysis is a set of very 
high quality SNPs that have passed numerous quality control tests and filters.  
Rare alleles are evaluated with LoFreq, which calls somatic variants using a 
Bonferroni-corrected P-value threshold of 0.05 [11]. Rare nucleotides are included in the 
final variant calling only if they pass two separate quality control steps: 1. The nucleotide 
is present in both overlapping sequence reads from a single DNA molecule and is called 
as a SNP when variants are called from the merged reads. 2. The nucleotide is called as a 
SNP twice in two separate instances of high-sensitivity variant calling, once for each 
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barcode file. The final outcome of the PELE-Seq analysis is very high quality SNPs that 
have passed numerous quality control tests and filters.  
 
 
Figure 3.1. Overview of Paired-End Low Error Sequencing (PELE-Seq) library 
generation. DNA libraries with a 100bp insert size are paired-end sequenced using 100bp 
reads, generating an overlap region of approximately 100bp. The overlapping reads are 
merged into a consensus sequence and mismatching bases are discarded. A mixture of 
two separate barcodes is ligated to each sample. In order to pass PELE-Seq quality 
filtering, SNPs must be present in both paired-end reads and with both barcodes.  
 
 
PELE-Seq Accuracy and Sensitivity 
 
We first sought to empirically determine the specificity and sensitivity of the 
PELE-Seq variant calling method. We sequenced control E. coli DNA mixtures 
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containing 64 known SNPs present at defined frequencies ranging from 0.1%-0.3%. The 
E. coli control DNA mixtures were generated using DNA from E. coli K12 substrain 
W3110 titrated into a much larger amount of DNA from E. coli B substrain Rel606. The 
K12 W3110 substrain of E. coli contains a SNP every ~117 bp compared to E. coli B 
substrain Rel606 [12,13]. The genome space sequenced was reduced to 14 kilobases by 
using Restriction-site Associated DNA Sequencing (RAD-Seq) to sequence only the 200 
nucleotides flanking an SbfI restriction enzyme cut site, [14]. SbfI cuts the sequence 
CCTGCAGG, which occurs ~70 times in the E. coli genome.  We identified the control 
SNPs by sequencing the pure E. coli K12 substrain W3110 and comparing it to pure E. 
coli B substrain Rel606. 
The identity and allele frequency of the E. coli SNPs in the control libraries was 
verified by sequencing to 25,000X average read depth (Table 3.1).  The total read depth 
listed is that of the processed bam file used for SNP calling; for PELE-Seq data the 
number of raw reads used to generate the final bam file is roughly 2.3 times this amount 
because of the overlapping stage of analysis. The rare alleles detected in the control 
libraries had allele frequencies ranging from 0.141-0.464% (1/200-1/710).  
We found that PELE-Seq had high sensitivity with no false positive SNP calls 
when detecting rare SNPs above 0.2% allele frequency and with read depths below 
30,000X (Figures 3.2, 3.3). When detecting rare alleles known to be present at 0.3% 
frequency, PELE-Seq was able to correctly identify 22 out of the 64 total SNPs present 
with no false positives, while standard DNA-Seq methods with high base-quality (>Q30) 
identified 17 true SNPs, and had a false positive rate of 30%.  
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 We compared the specificity of the PELE-Seq method to that of the previously 
developed “Overlapping Read Pair (ORP)” method of rare SNP detection in order to 
determine the benefit of using multiple barcodes and a custom analysis pipeline. When 
just overlapping read error correction was used, false positive SNP calls were made 
compared to the no false positives seen with PELE-Seq (Table 3.2). 
 
 
 
Table 3.1. Allele frequencies for known rare SNPs in control E. coli DNA mixtures 
labelled 1-4, sequenced to an average read depth of 25,000X. The rare alleles detected in 
the control libraries had average allele frequencies ranging from 0.21-0.30% or 1/330-
1/470 of total reads. 
 
 
 
PELE-Seq was 100% accurate at detecting rare alleles present at 0.3% with 
30,000X read depth, compared to a 74% average accuracy level for standard Non-PELE 
Q30+ data. However, sequencing with ultra-high read depths (above 30,000X) resulted in 
the occurrence of false positive mutations in the PELE-Seq data, resulting in a 90% 
accuracy level, compared to 70% for standard DNA-Seq Q30+ data. The accuracy of 
standard DNA-Seq Q30+ data remained constant around 70%, regardless of the read 
depth used.  
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Figure 3.2. Detecting SNPs present at 0.3% frequency in E. coli control libraries with 
PELE-Seq and standard DNA-Seq methods at 20,000X average read depth. The read 
depths of the individual barcode files are plotted in blue, and the total read depth is 
plotted in green. The SNPs detected with PELE-Seq are plotted in the inner circle, and 
the Non-PELE SNPs are plotted in the next outer circle. False positive mutations are 
designated with a red “X”. Of the 64 known SNPs present in the genome, PELE-Seq 
detected 22 mutations with 100% accuracy, compared to 17 mutations and 70% accuracy 
achieved with non-PELE methods. 
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Figure 3.3. Sequencing a control E. coli DNA library containing 64 rare SNPs present at 
0.3% allele frequency with PELE-Seq at 20,0000X read depth produces 100% accurate 
data, compared to 71% accuracy achieved with traditional sequencing methods. 
Traditional Non-PELE sequecning of the control libraries resulted in 7 false positive 
mutations, compared to zero with the PELE-Seq method. 
 
 
Detection of Rare and Putative De Novo Mutations in Wild and Lab-adapted C. remanei 
 
We applied PELE-Seq to track changes in the rare allele frequencies of a wild 
population of C. remanei nematode worms that was subjected to laboratory-adaptation. 
The ancestral (wild) C. remanei population originated from 26 mating pairs of nematodes 
that were expanded to a population of 1000+ individuals and then frozen within three 
generations [10]. A branch of this ancestral population was grown in the lab for 34 
generations, during which time it was culled randomly to a population of 1000 
individuals for each generation. The lab-adapted population was also subjected to 
2 freezes and 9 bleach treatments (hatchoffs) during this time. The numerous selection 
events endured by the lab-reared nematodes are expected to   lower genetic diversity of 
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the population via drift and bottlenecking. Rare advantageous SNPs may also be selected 
for during the process of lab-adaptation.  
 
 
 
 
 
 
Table 3.2. Total SNP calls of 0.3% rare allele spike in libraries with PELE-Seq, DNA-
Seq, and the ORP method. PELE-Seq data produces 100% accurate SNP calls, while 
standard DNA-Seq and the ORP method have accuracy rates of 71% and 82%, 
respectively. 
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To assess the changes in genetic diversity of the nematode population before and 
after lab-adaptation, DNA from the wild and laboratory-adapted populations of C. 
remanei worms was PELE-sequenced using PacI RAD-Seq. The PacI restriction enzyme 
cuts the sequence AATTAATT, which occurs 2044 times in the C. remanei caeRem3 
genome. In order to further decrease the complexity of the genome, we performed an 
additional restriction enzyme digestion with NlaIII to destroy a portion of the RAD tags 
in the library. NlaIII cuts the sequence CATG, which is present on approximately 30% of 
the PacI RAD tags. The resulting genome space covered was approximately 300 kb, 
which was sequenced to an average of 2000X read depth. 
We identified several differences between the SNPs present in the wild nematodes 
compared to those found in the lab-adapted population (Figure 3.4). We found SNPs 
present below 1% frequency that were unique to the wild or lab-adapted C. remanei 
populations, and the frequencies of some of these rare alleles changed dramatically 
during lab-adaptation. By plotting the allele frequencies of each SNP before and after lab 
adaptation, it is possible to visualize the changes in the allele frequencies of minor alleles 
in a population undergoing a response to selection. The most dramatic changes in SNP 
allele frequencies were observed in the rare SNPs (Figure 3.5). We identified 4658 
PELE-quality SNPs present below 1% frequency in the ancestral C. remanei population, 
and 2541 PELE-quality SNPs present below 1% frequency in the lab-adapted population. 
Of the 4658 SNPs that were present below 1% the ancestral C. remanei population, 958 
SNPs were still detected in the lab-adapted population, including 534 SNPs below 1% in 
the lab-adapted population. There were 14 SNPs that were found to increase in frequency 
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at least tenfold in the lab-adapted population compared to the ancestral population (Table 
3.3).   
  
 
 
Table 3.3. Fourteen SNPs present below 1% frequency in the wild C. remanei population 
increased in frequency at least 10x in the lab-adapted population. 
 
A SNP was detected at position 127,723,967 of the caeRem3 (WUSTL) genome 
that had increased in frequency by 43X in the lab-adapted population. The number of 
reads containing this G>C transversion jumped from 31/13000 (0.2%) in the wild 
population to 750/7000 (10.5%). This SNP is located upstream of the promoter region of 
a gene predicted by the UCSC Genome Browser to be homologous to the C. elegans gene 
ugt-5, a UDP- Glucuronosyltransferase (Figure 3.6). The reads mapping to this SNP in 
the Integrative Genome Browser (IGV) are shown in Figure 3.7. 
The lab-adapted worms also contained rare SNPs that were not detected in the 
wild population, including putative de novo mutations. We identified 287 rare variants 
that were present only in the lab-adapted C. remanei population. These rare alleles were 
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called with extremely high stringency by removing any SNPs that were called with either 
barcode file in the wild population from the analysis. The rare alleles appearing only in 
the lab-adapted population are all present below 0.8% allele frequency and are distributed 
throughout the genome (Figure 3.8). 
 
Methods 
 
Wild isolates of C. remanei from Koffler Scientific Reserve at Jokers Hill, King 
City, Toronto, Ontario were graciously provided by Asher Cutter’s lab (University of 
Toronto). “Isofemale strains” originating from 26 wild mating pairs were expanded to a 
population size of 2000 following the initial mating. All worms collected, and those in 
the experiment described below, were grown on nematode growth media (NGM) seeded 
with E. coli strain OP50. All collected strains were frozen within three generations of 
collection to minimize lab adaptation. To create a cohort representative of naturally 
segregating variation for experimental evolution, we thawed samples from each of the 26 
isofemale strains and crossed them in a controlled fashion to promote equal contributions 
from all strains, including from mitochondrial genomes and Y chromosomes. The 
resulting genetically heterogeneous population was frozen after creation and was the 
ancestral population used for the experiment. 
A lab-adaptation strain consisting of 1000-2000 mating individuals was 
propagated. The control populations were randomly culled to 1000 L1 larvae during each 
selective generation, for 23 generations. Each population was frozen (N≥100,000 
individuals) periodically to retain a record of evolutionary change in the populations and 
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to ensure that worms did not lose the ability to survive freeze and thaw. Approximately 
5000 individuals from the frozen populations were thawed to continue the evolution 
experiment, while the remaining 95,000 worms remained frozen for future phenotyping 
and genetic and genomic analyses. Populations were thawed for selection after a 
minimum of 24hrs at -80°C. Freezing occurred a total of 2 times during lab-adaptation 
selection. The lab-adapted population was also subjected to 11 rounds of bleaching/age-
synchronization. 
C. remanei genomic DNA was isolated using the DNeasy Tissue Kit (Qiagen). E. 
coli genomic DNA was acquired from REL606 strain (provided by the Bohannan lab, 
UO) and from W3110 strain (Life Technologies). 
Restriction-Site Associated DNA (RAD) Sequencing was used to reduce the 
complexity of the C. remanei genome. For this application we used the restriction 
enzyme PacI, which has an AT-rich cut site. The complexity of the PacI RAD library was 
further reduced by digestion with NlaIII, which destroyed ~30% of the total RAD tags. 
The resulting PELE-PacI-RAD-Seq library was sequenced at 2000X coverage. RAD tags 
were present at approximately every 10kb throughout the genome. 
Genomic DNA (2.0 μg) from each population was digested for 60 minutes at 37C 
in a 50 μL reaction volume containing 5.0 μL Buffer 1, 10 units (U) PacI (New England 
Biolabs [NEB]), and 0.5 μl 100X BSA (NEB). Samples were heat-inactivated for 20 min 
at 65 C. 1.0 μL of barcoded PacI-P1 adapter mixture (100 nM), a modified Illumina© 
adapter (2006 Illumina, Inc., all rights reserved; top oligo: 5’- 
ACACTCTTTCCCTACACGACGCTCTTCCGATCTxxxxx(xx)A*T -3’[xxxxx(xx) = 
barcode (TACGT, AGATCGA - ancestor; CTGCAA, GCTAGTC –evolved control), * = 
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phosphoro-thioate bond]; bottom oligo: 5’-Phos-
xxxxx(xx)AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTG*T-3’), was added to 
each sample along with 0.6 ml rATP (100 mM, Promega), 1.0 μl 10X NEB Buffer 4, 0.5 
μl (1000 U) T4 DNA Ligase (high concentration, NEB), 3.9 μl H2O and incubated at 
room temperature (RT) for 30 min. 
 
        
Figure 3.4. Total SNPs present in the wild and lab-adapted C. remanei populations. The 
inner yellow circle lists SNPs present in the lab-adapted population; the wild SNPs are 
listed in the blue circle. SNPs present in both the wild and lab-adapted populations are 
written with black letters. SNPs appearing in only the wild or lab-adapted populations are 
written with red letters. 
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Figure 3.5. The allele frequencies of SNPs in the ancestral and lab-adapted populations 
of C. remanei worms. Each point represents a SNP in the genome. Top) Allele 
frequencies before and after lab-adaptation for all SNPs detected that are present in both 
populations. SNPs in the top left corner are less frequent in the lab-adapted worms; SNPs 
in the bottom right corner are more frequent in the lab-adapted worms. The estimated 
0.25 and 0.75 quantiles of the square root of variance are shown for with the dashed red 
lines. Bottom) A zoom-in of allele frequencies for SNPs present below 1% in the wild C. 
remanei population, before and after lab-adaptation. Fourteen minor alleles present below 
1% in the wild population increased in frequency at least tenfold after lab adaptation. 
Only SNPs present in both populations are plotted. 
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Figure 3.6. A RAD tag sequenced with PELE-Seq contains a SNP at position 
127,723,967 of the caeRem3 (WUSTL) genome that maps to the predicted C. elegans 
gene ugt-5 that was increased in frequency by 44X after 34 generations of lab-adaptation. 
The UGT pathway is a major pathway responsible for the removal of drugs, toxins, and 
foreign substances. http://genome.ucsc.edu.  
 
 
 
 
Figure 3.7. A SNP near the promoter region of ugt-5 increases in frequency 43X after lab 
adaptation. A G>C transversion found at below 1% frequency in the ancestral C. remanei 
population has a 43X increase in frequency after 34 generations of laboratory adaptation. 
This SNP maps to the promoter region of predicted C. elegans gene ugt-5, which is an 
enzyme responsible for the removal of drugs, toxins, and foreign substances. The top 
panel shows the reads from the ancestral (wild) population mapping to the caerem3 
genome; the bottom panel shows the reads from the lab-adapted population. The non-
reference SNP at position 127,723,967 is visible in orange. 
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Figure 3.8. Allele frequencies and position of rare alleles detected only in the lab-
adapted C. remanei population with PELE-Seq. Each vertical line represents a single 
SNP; the height of the line is proportional to the allele frequency. The detected SNPs had 
allele frequencies ranging from 0.0021 to 0.0075. The UCSC caeRem3 genome from 
WUSTL is composed of a single artificial chromosome named chrUn that is 146 
megabases (Mb) long. 
 
Samples were again heat-inactivated for 20 min at 65C, combined, and randomly 
sheared (Bioruptor) to an average size of 140 bp. The sheared sample was purified using 
a QIAquick Spin column (Qiagen) and run out on a 1.25% agarose (Sigma), 0.5X TBE 
gel. A tight band of DNA from 130-150 bp was isolated with a clean razor blade and 
purified using the MinElute Gel Extraction Kit (Qiagen). The Quick Blunting Kit (NEB) 
was used to blunt the ends of the DNA in a 25 μl reaction volume containing 2.5 μl 10X 
Blunting Buffer, 2.5 μl dNTP Mix and 1.0 μl Blunt Enzyme Mix. The sample was 
purified and incubated at 37C for 30 min with 10 U Klenow Fragment (3’-5’ exo-, NEB) 
in a 50 μl reaction volume with 5.0 μl NEB Buffer 2 and 1.0 μl dATP (10 mM, 
Fermentas), to add 3’ adenine overhangs to the DNA. After another purification, 1.0 ml 
of Paired-End-P2 Adapter (PE-P2; 10 mM), a divergent modified Illumina© adapter 
(2006 Illumina, Inc., all rights reserved; top oligo: 5’-Phos-
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GATCGGAAGAGCGGTTCAGCAGGAATGCCGAGACCGATCAGAACAA-3’, 
bottom oligo: 5’-
CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTC
TTCCGATC*T-3’), was ligated to the DNA fragments at RT. The sample was purified 
and eluted in 50 μl. The eluate was digested again with NlaIII to reduce library 
complexity. The sample was column purified and eluted in 10 μl. Two separate PCR 
amplifications were performed with each sample, each using 5μl of eluate as template, in 
a 50 μl volume with 25 μl Phusion Master Mix (NEB) and 1.0 μl modified Illumina© 
amplification primer mix (10 mM, 2006 Illumina, Inc., all rights reserved; P1-forward 
primer: 5’ 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCC
GATC*T 3’, P2-reverse primer: 5’ CAAGCAGAAGACGGCATACG*A 3’). Phusion 
PCR settings followed product guidelines (NEB) for a total of 17 cycles with an 
annealing temperature of 65C. The libraries were pooled and cleaned through a column 
and gel purified, excising a tight band of DNA of 240 bp size. The sample was diluted to 
1 nM and sequenced on the Paired-end module of the Genome Analyzer II following 
Illumina protocols for 100 bp reads. 
Serial dilution of E. coli W3110 DNA with E. coli Rel606 DNA was performed to 
generate spike-in libraries with dilution levels ranging from 1:100 to 1:5000, at a 
concentration of 0.8 ng/μl. All dilutions were concentrated with a SpeedVac to 40 μl. 300 
ng of genomic DNA from each dilution was digested for 60 minutes at 37C in a 50 μL 
reaction volume containing 5.0 μL Buffer 4, 10 units (U) SbfI-HF (New England Biolabs 
[NEB]). Samples were heat-inactivated for 20 min at 65 C. 2.0 μL of barcoded SbfI-P1 
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adapter mixture (100 nM), a modified Illumina© adapter (2006 Illumina, Inc., all rights 
reserved; top oligo: 5’-Phos-
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCC
GATCTxxxxxxTGC*A 3’[xxxxxx = barcode (mixture of two barcodes per sample), * = 
phosphoro-thioate bond]; bottom oligo: 5’-Phos-
xxxxxxAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGGTC
GCCGTATCAT*T-3’), was added to each sample along with 0.6 ml rATP (100 mM, 
Promega), 1.0 μl 10X NEB Buffer 4, 0.5 μl (1000 U) T4 DNA Ligase (high 
concentration, NEB), 3.9 μl H2O and incubated at room temperature (RT) for 30 min. 
Samples were again heat-inactivated for 20 min at 65C, combined, and randomly sheared 
(Bioruptor) to an average size of 140 bp. The sheared sample was purified using 
Agencourt AMPure XP beads at a 1X volume. The Quick Blunting Kit (NEB) was used 
to blunt the ends of the DNA in a 50 μl reaction volume, and the sample was purified 
using Agencourt AMPure XP beads at a 1X volume. The sample was incubated at 37C 
for 30 min with 10 U Klenow Fragment (3’-5’ exo-, NEB) in a 50 μl reaction volume 
with 5.0 μl NEB Buffer 2 and 1.0 μl dATP (10 mM, Fermentas), to add 3’ adenine 
overhangs to the DNA. After another 1X bead purification, 1.0 ml of Paired-End-P2 
Adapter (PE-P2; 10 mM), a divergent modified Illumina© adapter (2006 Illumina, Inc., 
all rights reserved; top oligo: 5’-Phos-
GATCGGAAGAGCGGTTCAGCAGGAATGCCGAGACCGATCAGAACAA-3’, 
bottom oligo: 5’-
CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTC
TTCCGATC*T-3’), was ligated to the DNA fragments at RT. The sample was purified 
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and eluted in 40 μl. Ten separate PCR amplifications were performed with the sample, 
each using 4μl of eluate as template, in a 50 μl volume with 25 μl Phusion Master Mix 
(NEB) and 1.0 μl modified Illumina© amplification primer mix (10 mM, 2006 Illumina, 
Inc., all rights reserved; P1-forward primer: 5’ 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCC
GATC*T 3’, P2-reverse primer: 5’ CAAGCAGAAGACGGCATACG*A 3’). Phusion 
PCR settings followed product guidelines (NEB) for a total of 18 cycles with an 
annealing temperature of 65C. The libraries were pooled, cleaned through a QIAquick 
Spin column (Qiagen), and size selected with a Pippin Prep (Sage), collecting a tight 
band of DNA of 240 bp size. The sample was diluted to 1 nM and sequenced on the 
Paired-end module of an Illumina HiSeq 2500 following Illumina protocols for 100 bp 
reads.  
 
Discussion 
 
Current genomic studies of genetically heterogeneous samples, such as growing 
tumors acquiring de novo mutations, or natural populations that are difficult to sequence 
as individuals, are hampered by the difficulty in distinguishing alleles at low frequency 
from the background of sequencing and PCR errors. We have developed a method of rare 
allele detection that mitigates both sequence and PCR errors called PELE-Seq. PELE-Seq 
was evaluated using synthetic E. coli populations and used to compare a wild C. remanei 
population to a lab-adapted population. Our results demonstrate the utility of the method 
and provide guidelines for optimal specificity and sensitivity when using PELE-Seq. 
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By using PELE-Seq, we increased the number of independent validations of a rare 
SNP by sequencing each molecule twice with overlapping paired-end reads and by 
calling each SNP twice through the use of multiple barcodes. The multiple PELE-Seq 
quality control steps result in genotype calls of low-frequency alleles with a false positive 
rate of zero, allowing for the specific detection of rare alleles in genetically 
heterogeneous populations. 
We found that there is a window of sequencing depth that is ideal for detecting 
rare alleles when using PELE-Seq, and sequencing beyond this level will increase the 
probability of introducing false positive mutations due to PCR error. The ideal amount of 
coverage for a given library would depend on the specific PCR error rate of the method 
used to make the library. For our libraries, with an estimated PCR error rate of 0.05%, we 
found that the optimal level of read depth was around 25,000X coverage. Sequencing 
below this level reduced the sensitivity of the method, while sequencing above this level 
lead to the appearance of PCR errors in the data that were present in both barcoded 
libraries. 
Sequencing error reduction through the use of overlapping read pairs (ORPs) has 
been described previously by Chen-Harris et al., who show that the use of overlapping 
paired-end data dramatically reduces the occurrence of sequencing errors in NGS data 
[9]. Their group concluded that PCR error is the dominant source of error for sequencing 
data with an Illumina quality score above Q30, which they estimate to be around 0.05%. 
PELE-Seq adds to the overlapping read pair method by incorporating dual barcodes to 
filter out the PCR errors. We have shown that the PELE-Seq method has fewer false 
positives than sequencing data generated with the ORP method alone in our libraries.   
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We have used PELE-Seq to identify rare alleles in a wild C. remanei population 
whose frequencies have increased dramatically as result of laboratory cultivation, and we 
identify ultra-rare alleles that are only detectable after laboratory adaptation of a wild 
nematode worm population.  We identified a rare G > C transversion upstream of the 
promoter of ugt-5 that was increased in frequency 43X in the lab-adapted strain 
compared to the wild strain. UGT enzymes catalyze the addition of a glucuronic acid 
moiety onto xenobiotics and drugs to enhance their elimination. The UGT pathway is a 
major pathway responsible for the removal of most drugs, toxins, and foreign substances 
[15]. The striking increase in the frequency of this rare mutation after lab adaptation 
suggests that the surrounding genomic region is under positive selection. One possibility 
is that a change in ugt-5 expression may confer a growth advantage on the laboratory-
grown nematodes by increasing their ability to process and eliminate the bleach ingested 
during the hatchoff procedures. With PELE-Seq, it is possible to know that the ugt-5 SNP 
was present at a very low frequency in the wild population, and is not a de novo mutation. 
The SNPs detected only in the lab-adapted population were present at low frequencies, 
suggesting that pre-existing low-frequency minor alleles are the most useful source of 
genetic material available for C. remanei to respond to changes in the environment, as 
these alleles are readily available and don’t need to be spontaneously generated. In 
general, this approach should be useful for detecting changes in rare allelic variants in so-
called “evolve and reseq” experiments [16]. In this study, we sampled only a very small 
fraction (~1/500) of the C. remanei genome with RAD-Seq, and discovered multiple 
instances of apparent selection taking place.  
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We have demonstrated that the PELE-Seq method of variant calling is highly 
specific at detecting rare SNPs found at below 1% of a population. There were zero 
instances of false positive SNPs called from control sequenced E. coli library containing 
known rare alleles present at known frequencies. Previously, the high error rate of NGS 
resulted in thousands of false-positive SNPs that were indistinguishable from true minor 
alleles. The PELE-Seq method makes it possible to know with certainty the identity of 
rare alleles in a genetically heterogeneous population, and to detect ultra-rare and 
putative de novo mutations that aren’t present in an ancestral population. As a proof of 
principle, we have used PELE-Seq to identify rare mutations found in lab-adapted strains 
of C. remanei nematode worms. We identified a SNP in the lab-adapted worms that was 
increased in frequency 43X after 23 generations in the lab. This research demonstrates 
that model organisms grown in a laboratory can become genetically distinct from wild 
populations in a short period of time, and care must be taken when generalizing from 
conclusions drawn from research involving lab-reared organisms. 
In addition to sequencing rare alleles in a mixed population of individual 
organisms such as nematodes, PELE-Seq is useful for detecting de novo mutations in 
genetically heterogeneous environments such as tumors. The detection of rare mutations 
in a tumor is critical for an understanding of early tumorigenesis and tumor evolution.  
Sequencing tumors with standard NGS methods produces data containing an 
overwhelming number of false positive mutations, which cannot be distinguished from 
true mutations. PELE-Seq can filter out the false positive mutations in tumor sequencing 
data, and accurately identifying rare mutations. In Chapter IV, PELE-Seq is applied to 
detect rare mutations in the blood DNA of a human with disseminated osteosarcoma.  
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CHAPTER IV 
HIGH-SPECIFICITY TUMOR SEQUENCING 
 
Tumors are highly heterogeneous communities of cells that evolve through the 
accumulation of rare de novo mutations. Recently it has been shown that advanced 
tumors can actually contain several different types of genetically distinct cancer cells, 
each with a different prognosis and metastatic potential [1,2,3,4,5]. Tumor heterogeneity 
allows for tumor plasticity, and is a huge barrier preventing personalized cancer 
medicine. Because of tumor heterogeneity, a single biopsy often gives inaccurate and 
incomplete information regarding the genetic potential of a tumor. Often, the most 
aggressive cells in a tumor may represent only a fraction of the solid tumor and may not 
be detected in a standard single biopsy [6,7]. In addition, small and early tumors are 
difficult to extract and purify from nontumor cells, making their DNA challenging to 
detect. Because standard NGS methods cannot accurately detect rare mutations, we lack a 
clear understanding of the early tumor cascade of mutations that would represent the 
most attractive drug targets. A high-resolution systems-level understanding of the 
mutations involved in cancer progression is required. The PELE-Seq method was 
developed to improve the accuracy of rare mutation detection, and is described in Chapter 
III. As described below in Chapter IV, PELE-Seq was applied to sequence the blood 
DNA of an anonymous patient with disseminated metastases, and to identify the 
clinically-relevant mutations in the genome. Cancer patients often contain circulating 
tumor cells and cell-free DNA in their blood [8,9,10], and PELE-Seq can be used to 
accurately detect rare genetic variants found in the blood of a cancer patient.  
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PELE-Sequencing of a Human Osteosarcoma Blood Biopsy 
 
Under many circumstances, biopsies cannot be done due to the location and 
nature of a tumor. Additionally, biopsies give incomplete information when a tumor 
is large and heterogeneous, and the driver cells of the tumor or metastases are rare 
compared to the overall tumor. Cancer DNA from disseminated metastases can exist 
in the blood, lymph, or cerebrospinal fluid at low frequencies, and can be detected with a 
liquid biopsy. However, the rare mutations are often challenging to detect due to the high 
error rate of standard NGS techniques, as described in Chapter III. 
We applied PELE-Seq to sequence a whole-exome capture of blood DNA from an 
anonymous human patient with disseminated metastatic sarcoma, in collaboration with 
the Spellman lab at OHSU. We performed a PELE Sequencing and analysis, similar to 
that described in Chapter III, but without barcode information. The blood tumor DNA 
was sequenced to an average depth of coverage of 1000X, and screened for relevant 
mutations that are previously known to impact protein function in known cancer genes, 
based on evolutionary conservation of the affected amino acid in protein homologs 
[11,12].  
We identified ~5000 rare mutations passing quality filters that were present in 
disseminated osteosarcoma blood DNA. Of the mutations passing quality filters, 36 were 
functionally relevant mutations in known cancer genes (Table 4.1), including a mutation 
in PIK3CA present at 1.2%. Several other interesting mutations were also present in the 
blood DNA, including mutations in Atrx and Lrp1, which were present at around 0.1%.  
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Discussion 
 
Several of the mutations identified in the tumor blood sequencing are present in 
genes known to be involved in cancer initiation and progression. For example, Atrx is a 
known tumor suppressor [13], and Lrp1 is a known oncogene [14]. Unfortunately, none 
of the mutations discovered in the blood DNA of the anonymous osteosarcoma patient 
are currently targetable with cancer therapy drugs. Much work remains to determine the 
functional significance of the mutations discovered during this and other tumor 
sequencing projects. Cancer biologists have barely begun to understand the functional 
significance of the genetic variation of tumors, especially with regard to noncoding 
variants, including enhancer elements and noncoding RNAs [15,16]. The PELE-Seq 
method is a very useful and necessary first step in assessing and tracking the mutational 
landscape of the tumor environment. With PELE-Seq it is now possible to track the 
accumulation of mutations in a tumor, starting from early tumorigenesis, in order to 
identify the “driver mutations” responsible for tumor growth. The driver mutations of a 
tumor are very attractive drug targets because they are acquired early in tumor 
development and are probably necessary for the survival of the entire tumor [17]. Once 
we have a better understanding of the identity of all possible driver mutations for a tumor, 
one possible strategy involves treating a driver mutation before it is even detected in a 
tumor, which is the so-called “never mutation” approach [18]. Additionally, so-called 
“passenger mutations,” which are random de novo mutations that have accumulated over 
time due to the high mutation rate of tumors, also play a role in modifying tumor 
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progression and are important to track and understand as well [19]. PELE-Seq can be 
applied to understand the entire spectrum of mutations found in a tumor over time.  
PELE-Sequencing of blood biopsies and cell-free tumor DNA sequencing 
methods hold promise for future research for a basic understanding of tumor biology, as 
well as for clinical applications such as early detection and screening for relapse of 
recurrent metastases. Because the blood of a cancer patient with disseminated metastases 
contains a collection of DNA from various metastatic sites, sequencing the blood DNA 
would be very useful for detecting rare cancer mutations involved in tumor progression. 
PELE-Seq could also be very useful to predict the outcome of a drug therapy and to 
gauge the potential of tumor drug resistance, because it allows researchers to accurately 
assess the genetic potential of a tumor. In summary, PELE-Seq is an extremely useful 
method to understand tumor progression and metastases, and has many important 
applications in basic and clinical research. 
In addition to small de novo mutations, tumors often contain several types of 
genomic alterations, including large-scale amplifications, deletions, and rearrangements. 
Chapter V describes work done to identify large-scale rearrangements in the genome of 
advanced mouse glioblastoma tumors. 
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Table 4.1. Clinically relevant mutations detected in the blood DNA of an anonymous 
human patient with disseminated osteosarcoma, in collaboration with the Spellman lab at 
OHSU. Of the 5000+ rare variants identified in the blood DNA, 36 were predicted to be 
functionally relevant mutations affecting protein function in known cancer genes. The 
mutations detected are very rare compared to the majority of the blood DNA, with allele 
frequencies ranging from 0.1%-1%.  
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CHAPTER V 
MOUSE GLIOBLASTOMA GENOME SEQUENCING 
 
Cells must accumulate many mutations in order to acquire the hallmarks of 
cancer. In order to understand the evolutionary process of genome adaptation that these 
tumors undergo during malignant transformation, we must know which genes are 
mutated or altered during transformation. It is possible that there is a predictable 
sequence events leading to malignant transformation, and that certain early mutations are 
required for tumorigenesis. These early mutations, referred to as “driver mutations,” are 
very promising drug targets, as described in Chapter IV. Once identified, driver 
mutations can be screened for and treated in a rational manner, through the development 
of targeted drug therapies. Besides point mutations, tumors often contain many types of 
genetic alterations including small insertions and deletions, and large-scale alterations 
and rearrangements. Large scale rearrangements are difficult to detect with Next-
Generation Sequencing techniques, due to the short reads produced by the sequencers, the 
high error rate of the nucleotide sequence, and the high depth of coverage necessary to 
obtain the statistical power necessary to call a rearrangement [1,2]. 
The Mosaic Analysis with Double Markers (MADM) system in mice is a very 
useful tool for investigating early tumorigenesis and holds promise for the discovery of 
driver mutations [3]. MADM mice are engineered to lack tumor suppressor genes in a 
mosaic manner that resembles a natural loss-of-heterozygosity event in a human tumor. 
The tumors produced with the MADM system are superior to standard tumor suppressor 
knockout mice because the MADM system generates rare clonal tumors whose origins 
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more closely resemble human tumors. In addition, the MADM tumors can be identified 
by GFP expression. The GFP-labeled tumors can be dissected and studied with various 
techniques including DNA-Seq, RNA-Seq, immunohistochemistry, and flow cytometry. 
The work below describes the whole genome sequencing (WGS) of three such tumors 
dissected from mice engineered to lack functional p53 and Nf1genes in a small fraction 
of their neuroblasts, referred to as p53/Nf1 knockout (KO) MADM mice.  
 
 
Mosaic Analysis with Double Markers (MADM) Mouse Model of Glioblastoma 
 
The Mosaic Analysis with Double Markers (MADM) system allows for the 
creation of GFP-labeled mosaic tumors through simultaneous tumor suppressor deletion 
and GFP expression in rare mutant cells, generating realistic tumors that can be easily 
identified and studied. Because individual mutant cells are labeled, the MADM system 
allows for tumors to be analyzed in vivo at single-cell resolution. The mosaic double 
knockout of p53 and Nf1 has previously been shown to be an effective method of 
inducing glioblastomas in mice with high penetrance [3]. The p53/Nf1 KO MADM mice 
are engineered to contain the MADM p53/Nf1 cassette on chromosome 11. Upon 
tamoxifen injection, Cre is expressed in neuroblasts, leading to a small subset of cells 
undergoing sporadic inter-chromosomal mitotic recombination. The genomic 
rearrangement causes loss of heterozygosity (LOH) in the p53 and Nf1 genes, 
simultaneously with labeling of mutant cells, to generate uniquely identifiable 
homozygous mutant cells in a heterozygous background. These mice develop 
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glioblastoma with 100% penetrance and are an ideal mouse model for identifying early 
driver genes of glioblastoma. 
The MADM model has several advantages over traditional cancer models based 
on tumor suppressor deletion, allowing for more precise control of the in vivo tumor 
environment. GFP-labeling of tumor cells allows for cell lineage tracing throughout the 
metastatic process, while RFP-labeling of wild-type cells provides an internal control. 
Because MADM provides single-cell resolution, the initiation of tumorigenesis can be 
directly analyzed, making MADM an ideal system for discovering driver mutations of 
glioblastoma. 
In the p53/Kf1 KO MADM glioma model, p53 and Nf1 knockout alone is 
insufficient to cause malignant transformation. Typically only a small fraction of green 
(GFP-labeled) p53/Nf1 KO cells undergo malignant transformation. This observation 
provides support for the multi-hit hypothesis, which states that a cell must acquire several 
significant mutations for tumorigenesis to occur. Work in the Zong lab has shown that 
p53/Nf1 MADM knockout mouse neuroblasts do not transform into glioma cells until 
after they have become oligodendrocyte precursor cells (OPCs), implying that an 
important developmental step occurs in OPCs leading to glioma progression [4,5]. We 
sought to identify potential driver mutations of glioblastoma by sequencing advanced 
p53/Nf1 KO mouse gliomas and searching for mutations involved in OPC development 
and/or cell cycle regulation.  
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Mouse Glioblastoma DNA Sequencing 
 
The whole genomes of three gliomas from p53/Nf1 knockout MADM mice were 
sequenced at 4-6x average coverage with standard DNA-Seq, and aligned to the mm9 
mouse genome. Two of the tumors had matched nontumor samples that were also 
sequenced at 4-6x coverage (tumors 20641 and 20648). As expected, the tumor samples 
contained very few reads mapping to the deleted regions of the p53 and Nf1 genes. 
Sequencing reads mapping to exons 2-5 of the trp53 gene displayed on the Integrative 
Genomics Viewer (IGV) [6,7] are shown in Figure 5.1. The few wild type reads present 
in the knockout region are most likely due to immune and vessel cells in the tumor. 
Thousands of single nucleotide variants were identified in the tumor samples that 
were less frequent in the matched nontumor samples. The variants were assessed for 
predicted impact on protein function by the program SnpEff [8]. In tumor 20648, 16 
mutations were predicted to have a moderate functional impact in protein (Table 5.1). In 
tumor 20641, 18 mutations were predicted to have a moderate functional impact in 
protein (Table 5.2). However, none of the detected mutations in either tumor were known 
to be involved in OPC development, the cell-cycle, or any other frequently observed 
cancer processes. In addition, because of the low depth of coverage of the sequencing, it 
could not be ruled out that some variants may be strain-specific sequence variants that did 
not appear in the nontumor sequences due to statistical chance. Due to the lack of 
relevant point mutations discovered, the focus was switched to instead investigate large-
scale genome rearrangements. 
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Figure 5.1. Sequencing reads mapping to the p53 knockout regions of the glioblastoma 
MADM cassette on chromosome 11 of mouse genome mm10 for tumors 20641 and 
20648, and matched nontumor samples, using the Integrative Genome Viewer (IGV). The 
genomes of p53/Nf1 knockout MADM mice lack exons 2-4 of the gene Trp53 (p53). 
This is one of two specific regions lost due to homologous recombination of the MADM 
cassette in mouse neuroblasts.  
 
 
By plotting the coverage depth of the tumor genomes as a bigwig file on the 
UCSC genome browser [9,10], and scrolling through the genome in 10 megabase (Mb) 
sections, four large gene amplifications were identified in the three glioblastoma tumors. 
These amplifications were absent in the matched nontumor samples, which had low read 
coverage throughout the genome. Each tumor contained one or two large genome 
amplifications around a well-known cancer gene, as described below. Besides these four  
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Table 5.1. Tumor 20648 Mutations and allele frequencies in the nontumor and tumor 
genomes, aligned to mouse mm10 genome.  
 
 
Table 5.2. Tumor 20641 Mutations and allele frequencies in the nontumor and tumor 
genomes, aligned to mouse mm10 genome.  
 
large amplifications and the expected p53/Nf1 knockout, the tumor genomes were 
completely intact, with smooth and even coverage throughout the genome. Smaller 
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amplifications and deletions were present throughout the tumor genomes, but those were 
present in both the tumor and the matched nontumor samples.   
In tumor 20648, the smaller of the two tumors with matched nontumor tissue, a 
large, 400 kilobase (kb) amplification was discovered around the genes Ephb2 and Ephb8 
on chromosome 4 of the mouse genome, shown in Figure 5.2. Ephrins are a class of 
receptor tyrosine-kinases, cell-surface molecules involved in juxtacrine signaling. Ephb2 
is an ephrin receptor known to regulate glioma cell invasion [11,12]. Ephb2 and Ephb8 
are not normally expressed in OPCs. Aside from the large amplification around Ephb2, 
there are no other large amplifications or deletions in the entire genome. 
In tumor 20641, which was larger than tumor 20648, there were two separate 
large-scale amplifications, shown in Figures 5.3 and 5.4. Around the known glioblastoma 
oncogene MycN on chromosome 12, there was a 1.5 Mb amplification. There was also a 
6 Mb amplification around the gene Sox4 on chromosome 13, which is an important 
developmental gene for OPCs [13,14,15]. As in tumor 20648, aside from the two large 
amplifications, the tumor genomes are very intact and uniform, with even coverage 
throughout the genome.  
In the final tumor analyzed, which was sequenced previously without a matched 
nontumor sample, a 1 Mb amplification was discovered on chromosome 7. This genome 
amplification contained several genes, including Cd22, Nfkbid, and two Cox genes 
(Figure 5.5). 
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Figure 5.2. Sequencing reads that map to a 400kb region in chromosome 4 of mouse 
genome mm10 are ten times more abundant than reads mapping to other regions of the 
genome in tumor 20648. This 400kb region contains at least 5 genes, including Ephb2 
and Ephb8. http://genome.ucsc.edu.  
 
 
 
 
 
Figure 5.3. Sequencing reads that map to a 1.5Mb region in chromosome 12 of mouse 
genome mm10 are four times more abundant than reads mapping to other regions of the 
genome in tumor 20641. This amplified region contains the gene MycN, a known 
glioblastoma oncogene. http://genome.ucsc.edu.  
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Figure 5.4. Sequencing reads that map to a 6Mb region in chromosome 13 of mouse 
genome mm10 are five times more abundant than reads mapping to other regions of the 
genome in tumor 20648. This amplified region contains the gene Sox4, a known 
glioblastoma oncogene. http://genome.ucsc.edu.  
 
 
 
 
Figure 5.5. Sequencing reads that map to a 1Mb region in chromosome 7 of mouse 
genome mm10 are 500X more abundant than reads mapping to other regions of the 
genome. This amplified region contains the genes Cd22, Nfkbid, and many others. 
http://genome.ucsc.edu.  
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Discussion 
 
In the p53/Nf1 MADM glioblastoma mouse model, p53/Nf1 knockout alone is 
insufficient to cause malignant transformation. This suggests that additional mutations 
are required for the mutant cells to progress into a tumor, as predicted by the mulit-hit 
hypothesis [16]. The intertumor heterogeneity found in different brain tumor types may 
be caused by different somatic mutations or developmental origins, or a combination of 
both [17,18]. MADM-induced knockout of p53/Nf1 results in glioma only in OPC cells, 
suggesting that an important factor is expressed by OPCs that is required for malignant 
transformation, or that an important developmental switch exists within OPC cells that 
can lead to glioma when improperly activated. Another possibility is that specific 
mutations are sufficient to cause glioma, but only if they they occur in OPCs.  
Double-stranded DNA breaks and rearrangements are common in tumor genomes. 
Glioblastoma is known to have a higher incidence of chromothripsis, a large catastrophic 
genome rearrangement, compared to other tumor types [19]. However, not much is 
known about the extent of genome rearrangements in glioma tumors, as most studies of 
glioma heterogeneity focus on exome sequences or a few cancer genes [20,21]. The acute 
onset of typical glioma, and the higher incidence of chromothripsis suggest that genomic 
instability may be an important factor in glioma progression. In order to assess the 
genomic stability, whole genome tumor sequencing with matched nontumor samples is 
necessary to identify any large-scale chromosomal rearrangements not present in a wild-
type genome. 
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The three MADM glioblastoma tumors sequenced in this study were each found 
to contain one or two large genomic amplifications around known cancer oncogenes. 
Besides the large amplifications discovered, the tumor genomes were surprisingly intact, 
with smooth and even genome coverage throughout. Each tumor sequenced appears to 
have sustained its own independent genomic lesion near an oncogene, suggesting that 
double-stranded breaks are a common route to tumorigenesis in this type of mouse 
glioblastoma. These results imply that genomic instability leads to malignant 
transformation in glioblastoma, and that there are several possible genetic routes leading 
to tumorigenesis. The lack of genomic lesions around noncancerous genes appears to 
suggest that once an oncogenic amplification is introduced, it is quickly selected for by 
the tumor.  
Because the genome amplifications must have originated from double-stranded 
breaks, it is plausible that an upstream mutation exists which effects genome stability of 
OPCs. If there is indeed a SNP driving the genome amplification, it could be discovered 
by PELE-sequencing smaller tumors to higher depths of coverage, as described in 
Chapter IV. It is important to determine if such an upstream defect exists, as that would 
be a very attractive therapeutic target. However, it is possible that the genomic instability 
is simply due to random chance, in which case, the frequency of genomic amplifications 
in specific genes should be investigated with a larger sample size to uncover patterns of 
amplifications. A true understanding of the developmental and mutations origins of 
gliomagenesis will require a synthesis of the knowledge from developmental biology 
with our understanding of mutations and reorganizations that lead to malignant 
transformation.  
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CHAPTER VI 
CONCLUSION 
 
Next-Generation Sequencing (NGS) is a powerful tool that has revolutionized our 
understanding of genomic structure and variation for a diverse range of organisms. 
Unfortunately, NGS has some serious technical limitations due to the short sequencing 
read length and high nucleotide error rate produced by current NGS sequencing platforms 
such as Illumina. To address these issues, I have co-developed two new NGS techniques 
that improve current NGS genotyping and genome assembly, which are described in 
Chapters II and III. To improve genome assemblies resulting from short sequencing 
reads, local assembly of RAD-PE reads into contiguous sequences is employed to 
produce synthetic long reads for genome assembly, described in Chapter II. In order to 
improve the error rate of current NGS platforms, the Paired-End Low Error (PELE) 
Sequencing method was developed, which is a powerful method of sequencing rare 
genetic variants, described in Chapter III. Combined, these two new methods allow for 
the assessment of the total genetic potential of heterogeneous populations, including 
tumors, viral populations, microbiomes, and mixed pools of individuals, and for the 
understanding of the genomic architecture of various species.  
Tumor DNA sequencing is a technically challenging pursuit due to the highly 
heterogeneous nature of tumors which allows them to produce a wide range of different 
cell types with different genomes and different levels of aggressiveness. Biopsies often 
give an incomplete picture of the genetic capability of a tumor, especially for advanced 
tumors. The driver mutations of a tumor may exist in a rare “tumor stem cell” population 
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that is impossible to detect with standard NGS DNA Sequencing techniques. With PELE-
Seq it is now possible to know with certainty which rare variants are present in a tumor, 
which is crucial for an understanding of tumor initiation and progression. PELE-
Sequencing can also be used to detect tumor DNA in the blood of a cancer patient, as 
described in Chapter IV which described the PELE-Sequencing of the blood from a 
human osteosarcoma patient. With PELE-Seq, rare mutations below 1% were detected in 
the blood DNA that were predicted to impact protein function in known cancer genes. 
The Mosaic Analysis with Double Markers (MADM) mouse model of glioblastoma is an 
extremely useful tool for investigating early tumorigenesis, because it produces 
glioblastoma tumors in a mosaic manner that can be identified by green fluorescent 
protein (GFP) expression. By sequencing the whole genomes of three p53/Nf1 KO mouse 
glioblastomas, two of them with matched nontumorous DNA, each tumor was found to 
contain one or two large genomic amplifications not present in the wildtype mice. This 
work was described in Chapter V. The large genomic amplifications seem to have 
appeared quickly and suggest that double-stranded breaks in DNA are a common route of 
tumor evolution in mouse p53/Nf1 KO glioblastoma. 
Next-generation sequencing has opened the door to a new understanding of the 
variability and structure of living genomes. I have co-developed two new NGS methods 
that overcome the limitations of current NGS techniques: the short read length of the 
sequencing reads, and the high error of the nucleotide sequences generated. These 
techniques allow for much higher resolution when investigating genomic structure and 
variation, especially when sequencing heterogeneous populations of cells, such as 
tumors. It is now possible to know with certainty the number of polymorphisms present 
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in a genome, and to produce more complete genome assemblies using short sequencing 
reads. With these new tools to accurately assess genomes, there is much work to be done 
in order to uncover a functional understanding of living genomes. 
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